TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituxima…
Biotechnology
US, New York [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared TG Therapeutics, Inc. (TGTX) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 38,146.00 | 13,165.11 | 606.85 | 336.61 | -1,086.11 | 0.00 | 22.8147 | 42.97 | -0.8146 | -20.0921 | -0.08 | -0.09 | 6.6993 | - - | ||
| Maximum | - - | - - | - - | 1,535,067.00 | 609,984.00 | 35,800.00 | 99,050.00 | 5,421.00 | 0.02 | 1,336.3467 | 2,849.43 | 3.0051 | 85.3485 | 0.15 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -10,603.00 | -56,335.00 | -50,658.00 | 0.00 | -164.8536 | -132.82 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0844 | - - | ||
| Reata Pharmaceuticals, Inc. RETA | 172.36 | 0.04 0.02% | 1,909 vs. 954 | 6,566.00 | 22.00 | 192.00 | -70.00 | -1,490.00 | 5.1200 | 5.4820 | 0.0000 | 0.9628 | 8.4849 | 2.2110 | 0.3840 | 2.8209 | 38.00 | ||
| TG Therapeutics, Inc. TGTX | 35.07 | 0.52 1.51% | 2,573 vs. 3,774 | 5,459.00 | 63.00 | -10.00 | -8.00 | -1,525.00 | -0.0732 | -50.4229 | 0.0000 | 0.9130 | -0.1687 | -0.0669 | -0.0287 | 2.7564 | 155.00 | ||
| Madrigal Pharmaceuticals, Inc. MDGL | 347.45 | 18.21 5.53% | 532 vs. 386 | 7,578.00 | 0.00 | -147.00 | -149.00 | -1,483.00 | -7.3800 | -8.6674 | 0.0000 | 0.0000 | 0.0000 | -0.1734 | -0.1363 | 9.2623 | 21.00 | ||
| Exelixis, Inc. EXEL | 35.61 | 0.78 2.24% | 1,682 vs. 2,069 | 10,169.00 | 425.00 | 37.00 | 50.00 | -258.00 | 0.1200 | 47.8131 | 0.0000 | 0.9500 | 0.0878 | 0.0175 | 0.0133 | 3.2273 | 285.00 | ||
| Akero Therapeutics, Inc. AKRO | 32.73 | 1.53 4.90% | 824 vs. 554 | 2,284.00 | 0.00 | -53.00 | -35.00 | -627.00 | -0.9000 | -6.6902 | 0.0000 | 0.0000 | 0.0000 | -0.0630 | -0.0585 | 29.8643 | 69.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.